Our Pipeline
Our lead candidate, Vensobafusp alfa (KP104), is a novel bifunctional biologic that simultaneously and selectively blocks both the alternative and terminal complement pathways. KP104 is in Phase 2 clinical development for rare renal disorders and is anticipated to initiate Phase 3 studies in paroxysmal nocturnal hemoglobinuria (PNH). Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP701 is a novel, dual-acting anti-CD79BxCD32B monoclonal antibody for autoantibody-mediated disorders currently advancing to the clinic. These assets are investigational agents and have not yet been approved by any Health Authority, such as the FDA.